Sienna Biopharmaceuticals announced a $40 million financing deal with Silicon Valley Bank, $30 million of which it drew immediately upon closing. President and CEO Frederick Beddingfield characterized the terms of the loan agreement as “very favorable.” “We believe this additional, non-dilutive capital strengthens our balance sheet, extending our cash runway beyond our nine clinical data…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
